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ABSTRACT: A library of monosubstituted chalcones (1−17) bearing electron-
donating and electron-withdrawing groups on both aromatic rings were selected.
The cell viability on human tumor cell lines was evaluated first. The compounds
unable to induce detectable cytotoxicity (1, 13, and 14) were tested using the
monoamine oxidase (MAO) activity assay. Interestingly, they inhibit MAO-B,
acting as competitive inhibitors, with 13 and 14 showing the best profiles. In
particular, 13 exhibited a potency higher than that of safinamide, taken as a
reference. Docking studies and crystallographic analysis showed that in human
MAO-B 13 binds with the halogen-substituted aromatic ring in the entrance cavity,
similar to safinamide, whereas 14 is accommodated in the opposite way. The main conclusion of this cell biology, biochemistry, and
structural study is to highlights 13 as a chalcone derivative that is worth consideration for the development of novel MAO-B-
selective inhibitors for the treatment of neurodegenerative diseases.
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Chalcones are a key structure motif within the kingdomPlantae and are widely found in many edible plants.1
They are open-chain flavonoids in which a three-carbon α,β-
unsaturated carbonyl moiety joins the two aromatic rings and
are considered as open-chain intermediates in the synthesis of
flavones.2 This peculiar chemical structure endows chalcones
with the capability to hit different targets (enzymes and
receptors) and to exert a variety of biological activities. The
chalcone skeleton is therefore widely used in medicinal
chemistry and drug discovery3,4 to obtain derivatives with
anticancer, antioxidant, antiviral, and anti-inflammatory
activities and for the treatment of neurodegenerative
disorders.5−9
Chalcone derivatives exert their anticancer activity through
multiple mechanisms involving different targets,8,10 and various
targets are also responsible for the effect of chalcone analogues
on neurodegenerative diseases.11−13 In this latter field,
monoamine oxidases (MAOs) play an important role, being
mitochondrial and flavin adenine dinucleotide (FAD) cofactor-
dependent enzymes, which catalyze the oxidative deamination
of monoamine neurotransmitters.14 In particular, the MAO-B
isoform is mainly investigated for treatments of neuro-
degenerative disorders (including Parkinson’s and Alzheimer’s
diseases), while the MAO-A isoform mostly deals with
neurological and psychiatric disorders.14−16 In this connection,
although a number of MAO-A and MAO-B inhibitors are
already available in clinical practice, the need to reduce their
side effects and/or to improve their selectivity is still definitely
of interest and encourages studies aimed at developing novel
types of inhibitors.
The chalcone structure has been considered an interesting
non-nitrogen-containing scaffold.17−20 In a recent paper,
detailed structure−activity relationships (SAR) were discussed
for the inhibitory activity and selectivity toward MAOs, with
regard to the influence of different substituents on both
aromatic rings of chalcone derivatives and compounds
containing the chalcone motif.17 In particular, the introduction
of heterocycles, the presence of nitro groups or lipophilic
electron-donating groups, and halogen substitution on phenyl
ring A and/or B are some of the modifications that were
designed for the chalcone scaffold, and frequently, more than
one modification/substitution was introduced on the same
compound.17 On the basis of literature data, among the
simplest, less substituted chalcone derivatives, the most active
compounds against the MAO-B isoform are characterized by
the presence of hydroxyl and methoxy substituents at ortho and
para positions, respectively, of the A aromatic ring and a
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chlorine atom at the para position of the B ring. Nevertheless,
a role for each specific substituent did not emerge.12,13,17,18,21
In this frame, we focused our attention on a small library of
monosubstituted chalcone derivatives bearing an electron-
Table 1. Cell Growth Inhibition after 72 h of Incubation in the Presence of the Examined Chalcones and Safinamide
aValues are reported as mean ± SD of at least three independent experiments in duplicate.
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donating or electron-withdrawing substituent in the A or B
ring, with the aim to further clarify the function of the single
substituent in the biological properties. Such derivatives were
previously reported and studied as antiproliferative agents on
leukemia cells,22 and for them few or no data on MAO activity
were reported.19,23 All of the compounds were synthesized
using a classical Claisen−Schmidt condensation of the
appropriate acetophenone with the corresponding aldehyde
in a methanolic solution of sodium hydroxide. The products
were obtained after being recrystallized twice from ethanol
with a good grade of purity (see the Supporting Information).
As the absence of cytotoxicity is a mandatory requirement for
compounds to be used to treat neurodegenerative diseases, the
potential antiproliferative effects of the compounds belonging
to the library were evaluated on a wider number of human
tumor cell lines. The chalcone derivatives that were unable to
induce any significant antiproliferative effect were selected and
further studied as potential inhibitors for human recombinant
MAO-A and MAO-B. In detail, we evaluated the inhibition
constant values, the selectivity indices, and the mechanism of
inhibition. The kinetic characterization of the most interesting
derivatives, 13 and 14, integrated with docking studies and
crystallographic experiments uncovered their binding mode
inside the MAO-B active site. Overall, our findings expand the
knowledge in terms of possible molecular interactions between
the chalcone scaffold and MAO-B and highlight 13 as a
scaffold worth further study in view of the development of new
promising drugs for neurodegenerative diseases.
The absence of any cytotoxicity and the enzyme inhibition
mechanism are fundamental elements in the development of
novel MAO-B inhibitors to target neurodegenerative diseases.
With this aim, cell biology, biochemical, and structural studies
were combined to explore the activity profiles of a small library
of monosubstituted chalcones as potential MAO-B inhibitors.
Table 1 reports the chalcone series and the results on
antiproliferative activity, which was evaluated through an in
vitro assay performed on three tumor cell lines, i.e., A2780
(ovarian carcinoma), HT-29 (colorectal adenocarcinoma), and
MSTO-211H (biphasic mesothelioma). Data are expressed in
terms of the GI50 value, i.e., the concentration of compound
able to inhibit 50% cell growth with respect to the control
culture. Unsubstituted chalcone and safinamide were reported
as reference.
Interestingly, these results show that derivatives 1, 13, and
14 were unable to induce any cytotoxicity in any of the tested
cell lines. Otherwise, the majority of the chalcones belonging
to the selected library, as for the unsubstituted chalcone
scaffold, induced a significant antiproliferative effect, with GI50
values ranging from 2.8 to 16.7 μM. In particular, in the series
1−9 bearing an electron-donating or electron-withdrawing R2
substituent, derivative 2, characterized by the m-NO2 group,
showed the highest cytotoxic effect in all of the considered cell
lines (GI50 values ranging from 2.8 to 5.1 μM), while the o-
NO2 analogue 1 was completely ineffective on cells. For all of
the other derivatives (3−9), an intermediate effect was
observed.
With regard to 10−17, interesting differences in anti-
proliferative activity were observed for the derivatives bearing
CF3 as the R1 substituent (12−14). In detail, while the o-CF3-
substituted chalcone 12 was able to induce significant
cytotoxicity, the insertion of the same group at the meta
(13) or para (14) position abolished the effect on cells. For
10−11 and 15−17, the position of the NO2 or OCH3
substituent, respectively, did not significantly affect the
cytotoxicity. Finally, as expected, safinamide was completely
ineffective on human cancer cells.
On the basis of the antiproliferative activity data (Table 1),
the compounds devoid of detectable cytotoxic activity (GI50 >
20 μM) on all of the considered cell lines, i.e., 1, 13, and 14,
were selected and evaluated as potential inhibitors for human
recombinant MAO-A and -B enzymes using kynuramine (kyn)
as the substrate. Moreover, the most cytotoxic derivative 2,
unsubstituted chalcone, and compound 17, which had been
previously studied,19,23 were also tested as reference com-
pounds. Additionally, safinamide24 and isatin25 were included
in the study as reversible standard inhibitors of MAOs.
Figure 1. Competitive inhibition of chalcone derivatives on human MAO-B activity. Lineweaver−Burk double-reciprocal plots of MAO-B initial
velocity vs substrate concentration (1/v0 vs 1/[kynuramine]) in the absence and presence of various concentrations of compounds. Continuous
lines are the results of linear regression analysis of plotted data (r > 0.98). (a) Reciprocal plots at different concentrations of 13 (5−40 nM)
showing that increasing the concentration of the compound increases the effect on Km (from the x-intercept), while no effect on Vmax (from the y-
intercept) is observed. (b) Examples of reciprocal plots in the presence of 1, 14, and chalcone (the lead compound) that demonstrate their
competitive behavior (effect on Km only). Safinamide is shown as a standard competitive inhibitor. As these compounds have different inhibitory
potencies, different concentrations were used to show the effect on MAO-B.
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All of the tested chalcones were found to inhibit both MAO-
A and MAO-B. In particular, the Lineweaver−Burk double-
reciprocal plots (1/v0 vs 1/[S]) of the kinetic data for MAO-B
in the presence of various concentrations (5−40 nM) of 13
(Figure 1A) clearly demonstrate a competitive mode of
inhibition, as only the x-intercept (−1/Km) is affected by the
presence of the compound, in contrast to the y-intercept (1/
Vmax), which is not significantly different at all tested
concentrations. The reversibility of the inhibition was
evaluated by incubating MAOs with 13 (at a concentration
equal to 4 times the Ki value) for 20 min before starting
dialysis cycles. After dialysis, the MAO activity was fully
recovered, supporting the reversibility of the mode of
inhibition of this compound. The same behavior was found
for 1 and 14, as can be clearly seen in Figure 1B, where results
for the lead compound (chalcone) and safinamide are also
shown. This competitive behavior has been reported previously
for other chalcone derivatives.20,23
The values of the inhibition constant (Ki) for 1, 2, 13, 14,
and 17 were determined for both MAO-A and MAO-B and are
reported in Table 2 in a comparative analysis with the standard
inhibitors safinamide and isatin. From the data in Table 2, it
clearly appears that the presence of the −CF3 group as the R1
substituent (at the meta (13) or para (14) position of the
phenyl ring) significantly improves both the potency of the
inhibition and the selectivity toward the MAO-B isoform with
respect to unsubstituted chalcone. Otherwise, the insertion of
the −NO2 group as the R2 substituent at the meta position (1)
is detrimental to both MAO-B inhibition and the selectivity
index (S.I.).
In particular, compound 13 emerges as the most potent and
selective inhibitor for MAO-B. Indeed, its inhibition constant
value (Ki = 5.0 nM) is lower than that obtained for safinamide
(Ki = 17 nM), and it shows very good selectivity (S.I. = 920 vs
4820 of safinamide). Finally, derivative 17 is less potent (Ki =
22 nM) and less selective (S.I. = 594) than 13 under our
experimental conditions. It is worth mentioning that the Ki
value reported in Table 2 for 17 is lower than that previously
reported in the literature19,23 because it was determined under
different experimental buffer and temperature conditions. In
this regard, the 15−17 subseries was also tested previously on
MAO-B, and for both 15 and 16 a lower inhibitory potency
than for 17 was found.19,23
The noteworthy inhibitory potency (Ki value in the
nanomolar range) and the high selectivity exerted by 13
point to this derivative as one of the most promising chalcone
scaffolds for the development of agents for neurodegenerative
disease. Indeed, comparable effects on MAO-B have been
demonstrated only in a few trisubstituted18 and disubstituted13
chalcone derivatives and in a furan-based chalcone containing a
cinnamyl group.17 The relevance of 13 is further supported by
the absence of cytotoxicity also on nontumorigenic Met-5A
mesothelial cells, for which a GI50 value higher than 20 μM was
obtained, as for safinamide. In contrast, for the chalcone
scaffold and 17, cytotoxicity toward Met-5A was also
confirmed, with GI50 values of about 7.0 ± 1.5 and 11.8 ±
1.1 μM, respectively.
Overall these results prompted us to perform molecular
modeling studies on the most active compound of the series,
i.e., 13.
First, in silico ADME predictions made with QikProp
predicted that 13 has favorable drug-like properties and good
Table 2. Inhibition Constant Values and Selectivity Indices
for Human Recombinant MAO-A and MAO-B by 1, 13, and
14 and Also by Chalcone, 2, and 17 as Reference Chalcone




compound MAO-A MAO-B S.I.b
chalcone (14.6 ± 1.0) × 103 56 ± 6 260:1
1 (2.2 ± 0.2) × 103 400 ± 80 5.5:1
2 (2.5 ± 1.0) × 103 71 ± 11 35:1
13 (4.6 ± 0.5) × 103 5.0 ± 0.5 920:1
14 (9.2 ± 1.8) × 103 14.6 ± 0.1 630:1
17c (13.0 ± 2.1) × 103 21.9 ± 2.3 594:1
safinamided (82 ± 8) × 103 17 ± 4 4820:1
isatine (16 ± 3) × 103 (4 ± 1) × 103 4:1
aValues are reported as mean ± SD of three independent
experiments. bSelectivity index, given by S.I. = Ki(MAO-A)/
Ki(MAO-B).
cSee refs 19 and 23. dStandard MAO-B inhibitor.
eStandard MAO-A and MAO-B inhibitor.
Figure 2. Predicted docking poses of 13 in the MAO-A and MAO-B crystal structures: (a) binding mode of 13 in the MAO-A protein (PDB ID
2Z5X); (b) the more energetically favored binding mode (binding mode b) predicted for 13 in the MAO-B crystal structure (PDB ID 2V5Z).
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blood−brain barrier permeability (see Table S1). Then,
docking calculations into representative conformations of the
human MAO-A and MAO-B proteins were performed (see the
Supporting Information for the experimental details).24,26 In
particular, two different binding modes between 13 and MAO-
B were predicted (termed binding modes a and b), while a
single binding mode was observed for MAO-A. Figure 2a
shows the binding mode of 13 in MAO-A, and Figure 2b
depicts the more stable binding mode of 13 in MAO-B (herein
termed binding mode b). The less stable binding mode of 13
in MAO-B (binding mode a) is shown in Figure S1. The two
binding modes in MAO-B are likely due to the peculiar
morphology of this isoform, which is composed of two similar
subcavities separated by the Ile199 and Tyr326 side chains.27,28
The binding modes are similar to those previously reported for
other chalcone inhibitors.21,29
The docking scores in MAO-B were −10 kcal·mol−1 for
binding mode a and −11 kcal·mol−1 for binding mode b. The
docking score in MAO-A was −7.5 kcal/mol. To better
discriminate between the two binding modes in MAO-B, a
rescoring of the predicted docking poses was performed with a
more rigorous free-energy-based screening methodology (i.e.,
BEAR) to evaluate the binding free energy of the ligand.30
According to the binding free energy scores (ΔGbind)
predicted by BEAR, binding mode b of 13 turned out to be 6.8
kcal·mol−1 more stable than binding mode a (Table S2). In
binding mode b, the B phenyl ring of 13 establishes
hydrophobic interactions with the aromatic rings of the
Tyr398, Tyr435, and Tyr60 side chains and the flavine ring
of FAD. The α,β-unsaturated ketone binds close to the Ile198
and Leu171 side chains, with the carbonyl moiety forming a
hydrogen bond with the Cys172 side chain, as previously
observed for other chalcone compounds.29 The A ring forms
hydrophobic contacts with the Leu164, Leu167, Phe168 and
Trp119 side chains, as previously observed in ref 29. In
particular, the trifluoromethyl moiety was predicted to be
accommodated near the Trp119 and Leu164 side chains,
establishing close contacts. The hydrogen bond of the carbonyl
with the Cys172 residue is of special interest because this
residue, which is mutated to Asn181 in MAO-A, has a
recognized role in MAO-B/MAO-A selectivity.21,29 Impor-
tantly, docking of 13 into MAO-A did not provide an
orientation similar to that of MAO-B. In MAO-A, the
trifluoromethylbenzene moiety (ring A) was predicted to be
accommodated toward the entrance of the MAO-A binding
site near residues Leu97, Ile335, and Leu337 because of steric
clashes with the Phe208 side chain. Moreover, the carbonyl
group of 13 did not establish hydrogen bonds with MAO-A
residues. Interestingly, the lack of a hydrogen bond with
residues in this region of the MAO-A binding pocket, like
those previously observed with Cys172 or Tyr326 into MAO-
B, has been reported to play an important role in isoform
selectivity for the MAO proteins.27,28,31 The B phenyl ring is
accommodated close to the Tyr60 and Tyr407 side chains and
FAD, similar to what was observed in MAO-B. Altogether,
these differences help explain the experimentally observed
selectivity of compound 13 for MAO-B over MAO-A.
Considering that docking calculations on 13 suggested two
alternative orientations, one of which was clearly favored over
the other, we sought to investigate whether para (compound
14) instead of meta (compound 13) trifluorocarbon
substitution could play a role in discriminating the ligand
orientation. To this aim, the binding modes of 13 and 14 in
MAO-B were studied by X-ray crystallography. The three-
dimensional structures of human MAO-B in complex with 13
(Figures 3 and 4a) and 14 (Figure 4b) were solved at 2.3 and
2.1 Å resolution, respectively (statistics are reported in Table
S3). For both structures, the overall fold and, in particular, the
active site and the bound inhibitor display the same
conformation between the two monomers of the dimer
contained in the asymmetric unit (the root-mean-square
deviations for Cα atoms are 0.30 and 0.27 Å between chains
A and B for the structures in complex with compounds 13 and
14, respectively). Hereafter, we will refer to subunit A of each
structure for the following discussion.
Inspection of the electron density in the enzyme active site
revealed that 13 and 14 bind in the hydrophobic cavity of
MAO-B (Figure 4a,b, respectively). In both cases the chalcone
moiety is accommodated with the carbonyl oxygen pointing
toward the bottom of the active site and establishing a
hydrogen bond with Cys172 in one of the two conformations
that this residue adopts. This feature was also found in the
MAO-B structures in complex with chromone inhibitors.32
The distances between the cysteine side chain and the
chalcone alkene unit are 4.0 and 4.6 Å for 13 and 14,
respectively, both of which are too long for the formation of a
covalent bond as previously observed for other targets.33
Compound 13 binds with the CF3 substituent in the entrance
cavity space (Figure 4a), which is in agreement with the most
stable orientation predicted by modeling as described above
and is consistent with previous studies highlighting this part of
the active site as a favorable niche for halogen atoms (such as
in the case of safinamide; see Figure 5). Most likely, in the
crystallized MAO-B−13 complex the predicted binding mode
b of 13 is selected. Interestingly, 14 is bound in the opposite
way with respect to the flavin compared with 13, with the CF3
group positioned within the aromatic cage formed by residues
Tyr398 and Tyr435 in front of the flavin (Figure 4b). This is
unique in MAO-B structures and is probably due to the para
position of the substituent on the aromatic ring, which would
clash with the residues belonging to the gating loop formed by
residues 99−110 (on the left in Figure 4). Similar to the
Figure 3. Overall structure of the MAO-B dimer represented as a pink
ribbon diagram (chain A is on the left) with the membrane-spanning
C-terminal helix pointing to the bottom of the figure. The FAD
cofactor is shown in stick representation with carbon, nitrogen,
oxygen, and phosphorus atoms colored in yellow, blue, red, and
magenta, respectively. The structure in complex with 13 (in green,
with fluorine atoms in light blue and oxygen in red) is shown. The
overall fold is identical to that of the enzyme in complex with 14.
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fluorine atom substituent in safinamide, the CF3 group of 13 is
at the meta position and can easily be accommodated in the
entrance cavity. Superposition of the MAO-B structures in
complex with the two chalcone inhibitors highlights that the
carbonyl−Cys172 hydrogen bond functions as a sort of pivot
point by fixing the molecules in the active site and orienting
them in opposite directions with respect to the flavin (Figure
5). The chalcone scaffold is constrained by the flat and rigid
MAO-B cavity to position the inner aromatic ring
perpendicular to the flavin and the other slightly tilted, similar
to the conformation observed in safinamide (Figure 5).
Retrospective docking calculations predicted only one binding
mode for 14 (docking score of −10 kcal·mol−1), consistent
with the orientation observed in the crystal structure and
similar to the predicted binding mode a of 13 (Figure S2).
In conclusion, we report that among a library of
monosubstituted structurally related chalcones, three deriva-
tives (1, 13, and 14) demonstrated a safe profile on different
human cell lines and then were considered for further
investigation. In particular, 13 appeared to be good candidate
to target MAO enzymes in the context of neurodegenerative
diseases. Indeed, it behaves as competitive reversible inhibitor
of MAO-B, showing an inhibitory potency of Ki = 5 nM
(which is higher than that of the clinically used safinamide)
and a remarkable selectivity toward the MAO-B isoform.
Docking studies of the binding of 13 to MAOs confirmed the
strong affinity and selectivity for MAO-B versus MAO-A by
predicting opposite orientations in the active site of the two
isoforms (with the trifluoromethylbenzene moiety pointing
toward the FAD cofactor in MAO-B and toward the active-site
entrance in MAO-A). Crystal structures of MAO-B in complex
with 13 and 14 highlighted the key role played by the position
of the trifluoromethyl moiety on the phenyl ring (meta in the
former and para in the latter) in orienting the inhibitor into the
active site.
Overall, our studies pointed to 13 as a very promising
chalcone derivative to be considered for the development of
novel MAO-B-selective inhibitors for the treatment of
neurodegenerative diseases. The evaluation of its effectiveness
and nontoxicity in vivo and the effect on other targets involved
in neurodegenerative disorders warrant further investigation.
■ ASSOCIATED CONTENT
*sı Supporting Information
The Supporting Information is available free of charge at
https://pubs.acs.org/doi/10.1021/acsmedchemlett.1c00238.
Chemistry, materials and methods, molecular docking,
crystallographic details, and NMR spectra (PDF)
■ AUTHOR INFORMATION
Corresponding Authors
Lisa Dalla Via − Dipartimento di Scienze del Farmaco,
Universita ̀ degli Studi di Padova, Padova 35131, Italy;
orcid.org/0000-0002-9828-9388; Email: lisa.dallavia@
unipd.it
Figure 4. Architectures of the MAO-B active site in complex with (a) 13 and (b) 14. FAD is depicted as in Figure 3. The residues that line the
cavity are represented as sticks with carbon, nitrogen, oxygen, and sulfur atoms in pink, blue, red, and orange, respectively. The refined 2Fo − Fc
electron density map for the inhibitor molecule (contoured at 1.2σ) is shown in blue chicken-wire style. The fluorine atoms of both inhibitors are in
light blue, with carbon atoms in green (13) and gray (14). Water molecules are depicted as red spheres and hydrogen bonds as dashed lines.
Figure 5. Superposition of MAO-B structures in complex with 13, 14,
and safinamide (the latter represented with carbon atoms in magenta;
PDB code 2V5Z).24 For the sake of clarity, water molecules and
hydrogen bonds shown in Figure 4 have been omitted.
ACS Medicinal Chemistry Letters pubs.acs.org/acsmedchemlett Letter
https://doi.org/10.1021/acsmedchemlett.1c00238
ACS Med. Chem. Lett. 2021, 12, 1151−1158
1156
Michael S. Christodoulou − DISFARM, Sezione di Chimica
Generale e Organica “A. Marchesini”, Universita ̀ degli Studi
di Milano, Milano 20133, Italy; orcid.org/0000-0002-
5098-3143; Email: michail.christodoulou@unimi.it
Authors
Luca G. Iacovino − Dipartimento di Biologia e Biotecnologie,
Universita ̀ di Pavia, Pavia 27100, Italy
Luca Pinzi − Dipartimento di Scienze della Vita, Universita ̀
degli Studi di Modena e Reggio Emilia, Modena 41125, Italy
Giorgio Facchetti − DISFARM, Sezione di Chimica Generale
e Organica “A. Marchesini”, Universita ̀ degli Studi di Milano,
Milano 20133, Italy; orcid.org/0000-0002-1260-1335
Beatrice Bortolini − Dipartimento di Scienze del Farmaco,
Universita ̀ degli Studi di Padova, Padova 35131, Italy
Claudia Binda − Dipartimento di Biologia e Biotecnologie,
Universita ̀ di Pavia, Pavia 27100, Italy; orcid.org/0000-
0003-2038-9845
Giulio Rastelli − Dipartimento di Scienze della Vita,
Universita ̀ degli Studi di Modena e Reggio Emilia, Modena
41125, Italy; orcid.org/0000-0002-2474-0607
Isabella Rimoldi − DISFARM, Sezione di Chimica Generale e
Organica “A. Marchesini”, Universita ̀ degli Studi di Milano,
Milano 20133, Italy; orcid.org/0000-0002-6210-0264
Daniele Passarella − Dipartimento di Chimica, Universita ̀
degli Studi di Milano, Milano 20133, Italy
Maria Luisa Di Paolo − Dipartimento di Medicina
Molecolare, Universita ̀ degli Studi di Padova, Padova 35131,
Italy
Complete contact information is available at:
https://pubs.acs.org/10.1021/acsmedchemlett.1c00238
Author Contributions
∇L.G.I., L.P., and G.F. contributed equally
Notes
The authors declare no competing financial interest.
■ ACKNOWLEDGMENTS
M.L.D.P and L.D.V. are grateful for the financial support
provided from DOR (University of Padova). We thank
OpenEye Scientific Software, Inc., for a free academic license
for the OpenEye Toolkit. This work was supported by the
Italian Ministry of Education, University and Research
(MIUR) (Dipartimenti di Eccellenza Program 2018−2022,
Department of Biology and Biotechnology “L. Spallanzani”,
University of Pavia).
■ REFERENCES
(1) Rozmer, Z.; Perjési, P. Naturally occurring chalcones and their
biological activities. Phytochem. Rev. 2016, 15, 87−120.
(2) Di Carlo, G.; Mascolo, N.; Izzo, A. A.; Capasso, F. Flavonoids:
old and new aspects of a class of natural therapeutic drugs. Life Sci.
1999, 65, 337−353.
(3) Zhuang, C.; Zhang, W.; Sheng, C.; Zhang, W.; Xing, C.; Miao, Z.
Chalcone: a privileged structure in medicinal chemistry. Chem. Rev.
2017, 117, 7762−7810.
(4) Gandolfi, R.; Facchetti, G.; Christodoulou, M. S.; Fuse,̀ M.;
Meneghetti, F.; Rimoldi, I. Cascade reaction by chemo- and
biocatalytic approaches to obtain chiral hydroxy ketones and anti
1,3-diols. ChemistryOpen 2018, 7, 393−400.
(5) Singh, P.; Anand, A.; Kumar, V. Recent developments in
biological activities of chalcones: A mini review. Eur. J. Med. Chem.
2014, 85, 758−777.
(6) Schiano Moriello, A.; Luongo, L.; Guida, F.; Christodoulou, M.
S.; Perdicchia, D.; Maione, S.; Passarella, D.; Di Marzo, V.; De
Petrocellis, L. Chalcone derivatives activate and desensitize the
transient receptor potential ankyrin 1 cation channel, subfamily A,
member 1 TRPA1 ion channel: structure-activity relationships in vitro
and anti-nociceptive and anti-inflammatory activity in vivo. CNS
Neurol. Disord.: Drug Targets 2016, 15, 987−994.
(7) Quaglio, D.; Zhdanovskaya, N.; Tobajas, G.; Cuartas, V.;
Balducci, S.; Christodoulou, M. S.; Fabrizi, G.; Gargantilla, M.; Priego,
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